Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment

K. Chan, A. E. Clarke, R. Ramsey-Goldman, W. Foulkes, B. Tessier Cloutier, M. B. Urowitz, D. Gladman, O. Nived, J. Romero-Diaz, Michelle Petri, E. Ginzler, P. R. Fortin, S. C. Bae, D. J. Wallace, E. H. Yelin, Sasha Bernatsky

Research output: Contribution to journalArticle

Abstract

Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).

Original languageEnglish (US)
Pages (from-to)120-123
Number of pages4
JournalLupus
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Systemic Lupus Erythematosus
Estrogen Receptors
Breast Neoplasms
Progesterone Receptors
Radiotherapy
Drug Therapy
Therapeutics
Triple Negative Breast Neoplasms
Population
Registries
Neoplasms
human ERBB2 protein

Keywords

  • Breast cancer
  • estrogen
  • progesterone
  • receptor
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Chan, K., Clarke, A. E., Ramsey-Goldman, R., Foulkes, W., Tessier Cloutier, B., Urowitz, M. B., ... Bernatsky, S. (2018). Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment. Lupus, 27(1), 120-123. https://doi.org/10.1177/0961203317713146

Breast cancer in systemic lupus erythematosus (SLE) : receptor status and treatment. / Chan, K.; Clarke, A. E.; Ramsey-Goldman, R.; Foulkes, W.; Tessier Cloutier, B.; Urowitz, M. B.; Gladman, D.; Nived, O.; Romero-Diaz, J.; Petri, Michelle; Ginzler, E.; Fortin, P. R.; Bae, S. C.; Wallace, D. J.; Yelin, E. H.; Bernatsky, Sasha.

In: Lupus, Vol. 27, No. 1, 01.01.2018, p. 120-123.

Research output: Contribution to journalArticle

Chan, K, Clarke, AE, Ramsey-Goldman, R, Foulkes, W, Tessier Cloutier, B, Urowitz, MB, Gladman, D, Nived, O, Romero-Diaz, J, Petri, M, Ginzler, E, Fortin, PR, Bae, SC, Wallace, DJ, Yelin, EH & Bernatsky, S 2018, 'Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment', Lupus, vol. 27, no. 1, pp. 120-123. https://doi.org/10.1177/0961203317713146
Chan K, Clarke AE, Ramsey-Goldman R, Foulkes W, Tessier Cloutier B, Urowitz MB et al. Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment. Lupus. 2018 Jan 1;27(1):120-123. https://doi.org/10.1177/0961203317713146
Chan, K. ; Clarke, A. E. ; Ramsey-Goldman, R. ; Foulkes, W. ; Tessier Cloutier, B. ; Urowitz, M. B. ; Gladman, D. ; Nived, O. ; Romero-Diaz, J. ; Petri, Michelle ; Ginzler, E. ; Fortin, P. R. ; Bae, S. C. ; Wallace, D. J. ; Yelin, E. H. ; Bernatsky, Sasha. / Breast cancer in systemic lupus erythematosus (SLE) : receptor status and treatment. In: Lupus. 2018 ; Vol. 27, No. 1. pp. 120-123.
@article{497688891ad541ba8799fae6778e35c2,
title = "Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment",
abstract = "Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69{\%}) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81{\%}) were HER2 negative; seven of 26(27{\%}) were triple negative. All but one patient underwent surgery; 11.5{\%} received both non-tamoxifen chemotherapy and radiotherapy, 16.4{\%} radiotherapy without non-tamoxifen chemotherapy, and 14.7{\%} received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).",
keywords = "Breast cancer, estrogen, progesterone, receptor, systemic lupus erythematosus",
author = "K. Chan and Clarke, {A. E.} and R. Ramsey-Goldman and W. Foulkes and {Tessier Cloutier}, B. and Urowitz, {M. B.} and D. Gladman and O. Nived and J. Romero-Diaz and Michelle Petri and E. Ginzler and Fortin, {P. R.} and Bae, {S. C.} and Wallace, {D. J.} and Yelin, {E. H.} and Sasha Bernatsky",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/0961203317713146",
language = "English (US)",
volume = "27",
pages = "120--123",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Breast cancer in systemic lupus erythematosus (SLE)

T2 - receptor status and treatment

AU - Chan, K.

AU - Clarke, A. E.

AU - Ramsey-Goldman, R.

AU - Foulkes, W.

AU - Tessier Cloutier, B.

AU - Urowitz, M. B.

AU - Gladman, D.

AU - Nived, O.

AU - Romero-Diaz, J.

AU - Petri, Michelle

AU - Ginzler, E.

AU - Fortin, P. R.

AU - Bae, S. C.

AU - Wallace, D. J.

AU - Yelin, E. H.

AU - Bernatsky, Sasha

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).

AB - Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).

KW - Breast cancer

KW - estrogen

KW - progesterone

KW - receptor

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85038447514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038447514&partnerID=8YFLogxK

U2 - 10.1177/0961203317713146

DO - 10.1177/0961203317713146

M3 - Article

C2 - 28595511

AN - SCOPUS:85038447514

VL - 27

SP - 120

EP - 123

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 1

ER -